In a notable development in the pharmaceutical sector, a Pennsylvania federal judge has agreed to put on hold a class action lawsuit against Abbott and other drugmakers. The legal proceedings, which involve allegations of sham patent cases related to AndroGel, have been paused amidst indications that a settlement between the parties might be imminent. The case has drawn significant attention given its potential implications for patent law and pharmaceutical competition.
More details can be found in the original article on
Law360.